Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 4, Issue 2, 2003, Pages 119-123

  Tezcan, Hakan ^a   Yavuz, Dilek ^a   Toprak, Ahmet ^a   Akpinar, Ihsan ^a   Koç, Mehmet ^a   Deyneli, Oguzhan ^a   Akalin, Sema ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

ACE inhibition; Endothelial dysfunction; Insulin sensitivity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; GLUCOSE OXIDASE; GLYCERYL TRINITRATE; INSULIN;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD VESSEL INJURY; BRACHIAL ARTERY; CELL FUNCTION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; ENDOTHELIUM CELL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 0038489342     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2003.012     Document Type: Article

References (35)

1. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
2. Laakso M, Sarlund E, Mykkanen L. Essential hypertension and insulin resistance in non-insulin dependent diabetes. Eur J Clin Invest 1989;19:518-26.
3. McLaughlin T, Reaven G. Insulin resistance and hypertension. Geriatrics 2000;55:28-33.
4. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231:235-40.
5. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: Cause of the insulin resistance syndrome. Diabetes 1997;46(suppl 2):S9-S12.
6. Olsen MH, Andersen U, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A Life substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press 2000;9:132-9.
7. Natali A, Taddei S, Galvan AQ et al. Insulin sensitivity, vascular reactivity, and clamp induced vasodilatation in essential hypertension. Circulation 1997;96:849-55.
8. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertension 1999;12:205S-213S.
9. Cannon RO. Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. Am J Cardiol 1998;82(10A): 8S-10S.
10. Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND Study. Circulation 1996;94:258-65.
11. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotension II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 1999;35:60-6.
12. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678-84.
13. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000;36:575-80.
14. Feldman RD, Schmidt ND. Quinapril treatment enhances vascular sensitivity to insulin. J Hypertens 2001;19:113-18.
15. Ura N, Higashiura K, Shimamoto K. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 1999;44:153-9.
16. Akel A, Wiecek A, Nowicki M, Kokot F. The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension. Pol Arch Med Wewn 2000;103:123-31.
17. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22:1462-70.
18. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15.
19. Andersen TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-8.
20. Baumgartner-Parzer SM, Waldhausl WK. The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes 2001;109(suppl 2): S166-S179.
21. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
22. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
23. Lembo G, Morella A, Lanni F, Rozza F, Trimarco B. Vascular insulin resistance in hypertension. Nutr Metab Cardiovasc Dis 1997;7:126-7.
24. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
25. Cannon RO. Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. Am J Cardiol 1998;82(10A): 8S-10S.
26. Lonn EM, Yusuf S, Jha P et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
27. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.
28. Wilmink HW, Banga JD, Hijmering M, Erkelens WD, Stroes ESG, Rabeling TJ. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on post-prandial endothelial function. J Am Coll Cardiol 1999;34:140-5.
29. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-6.
30. Sun YP, Zhu BQ, Browne AE et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001;6:175-81.
31. Mullen MJ, Clarkson P, Donald AE et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomised, double-blind study. J Am Coll Cardiol 1998;31:1330-5.
32. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8.
33. Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ. Glucose transport activity in insulin resistant rat muscle. Diabetes 1996;45(suppl 1):S125-S128.
34. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001;14:921-6.
35. Muiesan ML, Salvetti M, Monteduro C et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999;33: 575-80.